Min Deng1,2,3, Shao-Hua Li1,2,3, Xu Fu4, Xiao-Peng Yan4, Jun Chen5, Yu-Dong Qiu6, Rong-Ping Guo7,8,9. 1. Department of Liver Surgery, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, China. 2. State Key Laboratory of Oncology in South China, Guangzhou, China. 3. Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. 4. Department of Hepatopancreatobiliary Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, 321 Zhong-Shan Road, Nanjing, Jiangsu, China. 5. Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China. 6. Department of Hepatopancreatobiliary Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, 321 Zhong-Shan Road, Nanjing, Jiangsu, China. yudongqiu510@163.com. 7. Department of Liver Surgery, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, China. guorp@sysucc.org.cn. 8. State Key Laboratory of Oncology in South China, Guangzhou, China. guorp@sysucc.org.cn. 9. Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. guorp@sysucc.org.cn.
Abstract
BACKGROUND: Programmed death- ligand 1 (PD-L1) seems to be associated with the immune escape of tumors, and immunotherapy may be a favorable treatment for PD-L1-positive patients. We evaluated intrahepatic cholangiocarcinoma (ICC) specimens for their expression of PD-L1, infiltration of CD8+ T cells, and the relationship between these factors and patient survival. METHODS: In total, 69 resections of ICC were stained by immunohistochemistry for PD-L1, programmed death factor-1 (PD-1), and CD8+ T cells. CD8+ T-cell densities were analyzed both within tumors and at the tumor-stromal interface. Patient survival was predicted based on the PD-L1 status and CD8+ T-cell density. RESULTS: The expression rate of PD-L1 was 12% in cancer cells and 51% in interstitial cells. The expression rate of PD-1 was 30%, and the number of CD8+ T-cells increased with the increase of PD-L1 expression (p < 0.05). The expression of PD-L1 in the tumor was correlated with poor overall survival(OS) (p = 0.004), and the number of tumor and interstitial CD8+ T-cells was correlated with poor OS and disease-free survival (DFS) (All p < 0.001). CONCLUSIONS: The expression of PD-L1 in the tumor is related to poor OS, and the number of tumor or interstitial CD8+ T-cells is related to poor OS and DFS. For patients who lose their chance of surgery, PD-L1 immunosuppressive therapy may be the focus of future research as a potential treatment.
BACKGROUND:Programmed death- ligand 1 (PD-L1) seems to be associated with the immune escape of tumors, and immunotherapy may be a favorable treatment for PD-L1-positive patients. We evaluated intrahepatic cholangiocarcinoma (ICC) specimens for their expression of PD-L1, infiltration of CD8+ T cells, and the relationship between these factors and patient survival. METHODS: In total, 69 resections of ICC were stained by immunohistochemistry for PD-L1, programmed death factor-1 (PD-1), and CD8+ T cells. CD8+ T-cell densities were analyzed both within tumors and at the tumor-stromal interface. Patient survival was predicted based on the PD-L1 status and CD8+ T-cell density. RESULTS: The expression rate of PD-L1 was 12% in cancer cells and 51% in interstitial cells. The expression rate of PD-1 was 30%, and the number of CD8+ T-cells increased with the increase of PD-L1 expression (p < 0.05). The expression of PD-L1 in the tumor was correlated with poor overall survival(OS) (p = 0.004), and the number of tumor and interstitial CD8+ T-cells was correlated with poor OS and disease-free survival (DFS) (All p < 0.001). CONCLUSIONS: The expression of PD-L1 in the tumor is related to poor OS, and the number of tumor or interstitial CD8+ T-cells is related to poor OS and DFS. For patients who lose their chance of surgery, PD-L1 immunosuppressive therapy may be the focus of future research as a potential treatment.
Authors: Mina Komuta; Olivier Govaere; Vincent Vandecaveye; Jun Akiba; Werner Van Steenbergen; Chris Verslype; Wim Laleman; Jacques Pirenne; Raymond Aerts; Hirohisa Yano; Frederik Nevens; Baki Topal; Tania Roskams Journal: Hepatology Date: 2012-06 Impact factor: 17.425
Authors: John Bridgewater; Peter R Galle; Shahid A Khan; Josep M Llovet; Joong-Won Park; Tushar Patel; Timothy M Pawlik; Gregory J Gores Journal: J Hepatol Date: 2014-03-27 Impact factor: 25.083
Authors: Michelle L DeOliveira; Steven C Cunningham; John L Cameron; Farin Kamangar; Jordan M Winter; Keith D Lillemoe; Michael A Choti; Charles J Yeo; Richard D Schulick Journal: Ann Surg Date: 2007-05 Impact factor: 12.969
Authors: Ulrich Sommer; Celina Ebersbach; Alicia-Marie K Beier; Gustavo B Baretton; Christian Thomas; Angelika Borkowetz; Holger H H Erb Journal: Front Mol Biosci Date: 2022-06-28